Menotrophin Ferring

Menotrophin, the active ingredient in Menotrophin Ferring, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It treats infertility related to anovulation and supports ovarian stimulation in assisted reproductive technologies.

GNH USA supplies Menotrophin Ferring as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

Menotrophin acts on the reproductive hormone axis to address several infertility‑related conditions.

Infertility due to anovulation: stimulates follicular growth to enable ovulation in women who do not ovulate spontaneously. Controlled ovarian stimulation for assisted reproductive technology (e.g., IVF): provides FSH/LH activity to develop multiple follicles for egg retrieval. Induction of ovulation in hypogonadotropic hypogonadism: replaces deficient gonadotropins to trigger ovulation in women with low endogenous FSH/LH.

Menotrophin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain or erythema - Mild abdominal discomfort or bloating - Headache - Nausea or mild vomiting - Transient ovarian hyperstimulation (mild) - Fatigue

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS) - Multiple pregnancy - Allergic reaction or anaphylaxis - Thromboembolic events - Severe abdominal pain or ascites - Visual disturbances or blurred vision

When using Menotrophin, clinicians should observe several safety measures.

Monitor ovarian response: use ultrasound and estradiol levels to adjust dose. Avoid in active ovarian cysts: risk of rupture or exacerbated symptoms. Assess for hypersensitivity: discontinue if severe allergic reaction occurs. Use caution in patients with thromboembolic risk: monitor for signs of clot formation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotrophin can interact with other medications that affect hormonal balance or clotting.

Major Interactions (Avoid): - GnRH agonists: may amplify ovarian response, increasing OHSS risk. - Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy. - Medications that raise estrogen levels: may heighten OHSS risk.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for thrombotic events. - Diabetes medications: monitor glucose if OHSS develops. - Corticosteroids: may affect hormone metabolism and response.